For the acute treatment of migraine and the preventive treatment of episodic migraine in adults.

The First and Only Medication Proven to Treat and Prevent Migraines[1,2]


The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

Richard B. Lipton, M.D., Robert Croop, M.D., Elyse G. Stock, M.D., David A. Stock, Ph.D., Beth A. Morris, B.A., Marianne Frost, M.A., Gene M. Dubowchik, Ph.D., Charles M. Conway, Ph.D., Vladimir Coric, M.D., and Peter J. Goadsby, M.D., Ph.D.


THE LANCET

www.thelancet.com

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

Robert Croop, Richard B Lipton, David Kudrow, David A Stock, Lisa Kamen, Charles M Conway, Elyse G Stock, Vladimir Coric, Peter J Goadsby

Lancet 2020; Published Online December 15, 2020 https://doi.org/10.1016/S0140-6736(20)32544-7

Phase 3 trials of Nurtec were published in *The New England Journal of Medicine* and *The Lancet*.[2,12]

What is it?[1]

Nurtec ODT is a quick dissolve oral CGRP receptor antagonist

How it's dosed:[1]

Nurtec ODT 75 mg PRN once daily for **acute** treatment of migraine or

Nurtec ODT 75 mg every other day for **prevention** of episodic migraine

Up to 18 doses of Nurtec ODT can be taken per month[1]

Well tolerated for acute and preventive treatment. The most common adverse events were nausea (2.7%) and abdominal pain/dyspepsia (2.4%).[1]

Nurtec ODT is supplied in a carton containing an 8-pack[1]

Key characteristics:

- Works quickly to resolve pain and gets many patients back to normal activities in 1 hour[1,3-5]
- Sustained effects for 48 hours after a single dose for many patients[1,3,6]
- Customize therapy from acute to prevention[1]
- Has no contraindications in patients with cardiovascular disease or hypertension[1,8]
- Allows for migraine treatment without vasoconstrictive effects[1,7,9-11]
- Nurtec ODT needs no titration[1]
- The CGRP mechanism of action is not associated with rebound headaches[7]

How to get Nurtec® ODT (rimegepant):

Take the headache out of starting your patients on Nurtec ODT

To ensure 100% access to your commercially insured patients and to get personalized support for you and your patients call **1-833-4NURTEC** and a Nurtec OneSource conceirge will assist you.

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

IMPORTANT SAFETY INFORMATION continued on next page.

Please see full Prescribing Information here.

Dissolving the line between acute and preventive treatment for migraines.[1,2]

STUDY DESIGNS

For the acute indication, Nurtec ODT was evaluated in a multi-center, double-blind, randomized, placebo-controlled study of 1351 patients (Nurtec ODT 75 mg, n=669; placebo, n=682), with co-primary endpoints at 2 h for Nurtec ODT vs placebo: pain freedom (21% vs 11%, *P*<.001) and freedom from most bothersome symptom (MBS; predefined as photophobia, phonophobia, or nausea; 35% vs 27%; *P*=.001).[1]

For the preventive indication, Nurtec ODT 75 mg was evaluated in a multi-center, double-blind, randomized, placebo-controlled study of 695 patients (Nurtec ODT 75 mg, n=348; placebo, n=347) with the primary endpoint being change from baseline in the mean number of monthly migraine days during weeks 9-12 (-4.3 vs -3.5, *P*=.01).[1]

IMPORTANT SAFETY INFORMATION continued

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations: *Pregnant/breast feeding:* It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. *Hepatic impairment*: Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment*: Avoid use in patients with end-stage renal disease.

INDICATION

Nurtec ODT is indicated in adults for the:
- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

Please see full Prescribing Information here.

Price disclosure information for prescribers available here: Nurtec-HCP.com/pricing

REFERENCES: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals, Inc. **2.** Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. *Lancet*. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7. **3.** Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. *Lancet*. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. **4.** Data on File. RIM108. Biohaven Pharmaceuticals Inc. **5.** Lipton RB, Coric V, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg orally dissolving tablet for the acute treatment of migraine: a phase 3, double-blind, randomized, placebo-controlled trial (study 303). Abstract presented at: *61st Annual Scientific Meeting of the American Headache Society*; Philadelphia, PA. Session IOR05; July 11, 2019. **6.** McGinley JS, L'Italien GJ, Thiry AC, et al. Rimegepant 75 mg results in reductions in monthly migraine days: Secondary analysis of a multicenter, open label, long-term safety study of rimegepant for the acute treatment of migraine. Virtual Poster presented at: *American Academy of Neurology 2020 Annual Meeting*; April 17, 2020. **7.** Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the Trigeminal System in Migraine. *Headache*. 2019;59(5):659-681. doi: 10.1111/head.13529. **8.** Data on File. RIM130. Biohaven Pharmaceuticals Inc. **9.** Durham PL. CGRP-Receptor Antagonists — A Fresh Approach to Migraine Therapy? *N Engl J Med*. 2004;350(11):1073-1075. doi: 10.1056/NEJMp048016. **10.** Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. *Physiol Rev*. 2017;97(2):553-622. doi: 10.1152/physrev.00034.2015. **11.** Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies — successful translation from bench to clinic. *Nat Rev Neurol*. 2018 Jun;14(6):338-350. doi: 10.1038/s41582-018-0003-1. **12.** Lipton RB, Croop R, Stock EG, et al. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. *N Engl J Med*. 2019;381(2):142-149. doi: 10.1056/NEJMoa1811090.

biohaven pharmaceuticals

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

US-RIMODT-2100888 10/29/2021